Business
HARMONY BIOSCIENCES CONTINUES COMMUNITY COMMITMENT IN 2023 WITH PATIENTS AT THE HEART AND PROGRESS AT THE HEART NONPROFIT FUNDING PROGRAMS
The annual funding programs support patient-centric initiatives within rare neurological disease and sleep disorder communities Applications for Patients at
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":"The annual funding programs support patient-centric initiatives within rare neurological disease and sleep disorder communities \nApplications for Patients at the Heart and Progress at the Heart open today, Tuesday, February 28, timed to \"Rare Disease Day\"\nPLYMOUTH MEETING, Pa., Feb. 28, 2023 /PRNewswire/ -- Community and nonprofit organizations throughout the country that are working to support patient-centric initiatives within rare neurological diseases and sleep disorders will have the opportunity to receive funding to support innovative initiatives, thanks to the continuation of Harmony Biosciences' Patients at the Heart and Progress at the Heart programs. Harmony Biosciences (\"Harmony\") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, launched the programs in 2019 and 2021, respectively, and today announced the reopening of the application period for 2023.\n\n \n \n \n \n \n \n\n \nThe annual programs have supported diverse initiatives ranging from a retreat to provide rare disease caregivers with new skills to care for their loved ones and develop their own self-care practices to a behavioral and educational program for underrepresented high school students to raise awareness of the importance of healthy sleep for the prevention of cardiovascular and other chronic diseases. \nBoth the Patients at the Heart and Progress at the Heart funding programs provide opportunities for organizations providing innovative, comprehensive, and patient-centric initiatives that either directly support the unique challenges and profound needs of people living with sleep disorders and rare neurological diseases who experience excessive daytime sleepiness (EDS) or help achieve greater equality within rare neurological disease communities.\n\"People living with sleep disorders often face stigma from a lack of understanding about their diagnosis and the needs that follow,\" said Claire Wylds-Wright, MFA, CEO of the Hypersomnia Foundation, a 2022 Patients at the Heart program recipient for their #UNIGHT program, an initiative that fosters peer-to-peer support for individuals with sleep disorders. \"The Patients at the Heart funding enabled us to address the psychosocial challenges tied to sleep disorders by bringing individuals together in...